Semaglutides cardiovascular benefit data (the SELECT trial, 2023) remains a distinct advantage for high-risk patients, and this consideration may guide some providers to recommend semaglutide even for patients currently on tirzepatide
Another approach is to inject on a day that strategically manages your appetite through the week
Plus, our team gives expert supplement advice so you can get the best results from every scoop.
it addresses multiple cardiovascular risk factors, including dyslipidemia, hypertension, and obesity, making it a cornerstone in the comprehensive management of T2D patients with ASCVD
"Because obesity is a chronic, progressive, and relapsing disease, weight regain is inevitable once you withdraw the medication," he said